| Title: |
The Complexity of Treatments and the Multidisciplinary Team—A Rare Case of Long-Term Progression—Free Survival in Prostate Cancer until Development of Liver and Brain Metastases |
| Authors: |
Roxana-Andreea Rahnea-Nita; Laura-Florentina Rebegea; Alexandru Nechifor; Cristian Mareș; Radu-Valeriu Toma; Alexandru-Rares Stoian; Anda-Natalia Ciuhu; Liliana-Florina Andronache; Georgiana Bianca Constantin; Gabriela Rahnea-Nita |
| Source: |
Journal of Clinical Medicine, Vol 12, Iss 5579, p 5579 (2023) |
| Publisher Information: |
MDPI AG |
| Publication Year: |
2023 |
| Collection: |
Directory of Open Access Journals: DOAJ Articles |
| Subject Terms: |
prostate cancer; liver and brain metastases; long-term survival; Medicine |
| Description: |
Introduction: Prostate cancer has no initial clinical manifestation in the case of brain metastases since they are asymptomatic at first. This is why there is a high risk for clinicians to overlook these lesions, and they are often confused with other diseases. With all the improvements in diagnostic technological methods, which allow the early detection of lesions, and the progress in terms of systemic therapy associated with increased survival, an increase in incidence has also been noticed. Materials and methods: We report the case of a 64-year-old patient who presented himself to the Oncology Department of “St. Luca” Chronic Disease Hospital in Bucharest in November 2011 and received the following diagnosis: biopsied prostate neoplasm, local-regionally advanced, pelvic lymph node metastases. Results: After receiving complex oncological treatment, this patient represents a rare case of long-term progression-free survival (15 years). Discussions: This case has some particularities. According to the literature data, survival with metastatic prostate cancer is approximately 21 months, and cerebral metastases are found in only 2% of prostate cancer cases. This case is one of the few cases in the specialty literature that benefited from all therapeutic sequences; namely, total androgenic blockade, docetaxel, abiraterone, enzalutamide, and cabazitaxel. Conclusions: Brain metastases are an unfavorable prognostic factor in prostate cancer. The therapeutic options developed in recent years allow the improvement of survival. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
https://www.mdpi.com/2077-0383/12/17/5579; https://doaj.org/toc/2077-0383; https://doaj.org/article/20103801f0c94710848463edf7d248da |
| DOI: |
10.3390/jcm12175579 |
| Availability: |
https://doi.org/10.3390/jcm12175579; https://doaj.org/article/20103801f0c94710848463edf7d248da |
| Accession Number: |
edsbas.5189A04D |
| Database: |
BASE |